{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:34:14Z","timestamp":1790534054091,"version":"4.1.0"},"reference-count":133,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Duchenne muscular dystrophy (DMD) is the most common childhood muscular dystrophy affecting ~1:5000 live male births. Following the identification of pathogenic variations in the dystrophin gene in 1986, the underlining genotype\/phenotype correlations emerged and the role of the dystrophin protein was elucidated in skeletal, smooth, and cardiac muscles, as well as in the brain. When the dystrophin protein is absent or quantitatively or qualitatively modified, the muscle cannot sustain the stress of repeated contractions. Dystrophin acts as a bridging and anchoring protein between the sarcomere and the sarcolemma, and its absence or reduction leads to severe muscle damage that eventually cannot be repaired, with its ultimate substitution by connective tissue and fat. The advances of an understanding of the molecular pathways affected in DMD have led to the development of many therapeutic strategies that tackle different aspects of disease etiopathogenesis, which have recently led to the first successful approved orphan drugs for this condition. The therapeutic advances in this field have progressed exponentially, with second-generation drugs now entering in clinical trials as gene therapy, potentially providing a further effective approach to the condition.<\/jats:p>","DOI":"10.3390\/jcm10040820","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T21:35:42Z","timestamp":1613597742000},"page":"820","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy"],"prefix":"10.3390","volume":"10","author":[{"given":"Fernanda","family":"Fortunato","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-4798","authenticated-orcid":false,"given":"Rachele","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5619-628X","authenticated-orcid":false,"given":"Maria Sofia","family":"Falzarano","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8385-9870","authenticated-orcid":false,"given":"Alessandra","family":"Ferlini","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, University of Ferrara, 44121 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/0092-8674(87)90504-6","article-title":"Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals","volume":"50","author":"Koenig","year":"1987","journal-title":"Cell"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1474-4422(03)00585-4","article-title":"Dystrophin and mutations: One gene, several proteins, multiple phenotypes","volume":"2","author":"Muntoni","year":"2003","journal-title":"Lancet Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3389\/fgene.2020.00131","article-title":"The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study","volume":"11","author":"Neri","year":"2020","journal-title":"Front. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"18168","DOI":"10.3390\/molecules201018168","article-title":"Duchenne Muscular Dystrophy: From Diagnosis to Therapy","volume":"20","author":"Falzarano","year":"2015","journal-title":"Molecules"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13073-017-0479-0","article-title":"Next-generation mapping: A novel approach for detection of pathogenic structural variants with a potential utility in clinical diagnosis","volume":"9","author":"Barseghyan","year":"2017","journal-title":"Genome Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"91F","DOI":"10.1136\/fn.86.2.F91","article-title":"Newborn screening for Duchenne muscular dystrophy: A psychosocial study","volume":"86","author":"Parsons","year":"2002","journal-title":"Arch. Dis. Child. Fetal Neonatal Ed."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s10897-018-0266-0","article-title":"Experiences of Women Who Have Had Carrier Testing for Duchenne Muscular Dystrophy and Becker Muscular Dystrophy During Adolescence","volume":"27","author":"Fraser","year":"2018","journal-title":"J. Genet. Couns."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s40291-019-00385-2","article-title":"Non-invasive Prenatal Testing Using Fetal DNA","volume":"23","author":"Breveglieri","year":"2019","journal-title":"Mol. Diagn. Ther."},{"key":"ref_9","unstructured":"(2020, December 18). The DMD Gene Homepage. Available online: https:\/\/databases.lovd.nl\/shared\/genes\/DMD."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/mus.20586","article-title":"Entries in the Leiden Duchenne muscular dystrophy mutation database: An overview of mutation types and paradoxical cases that confirm the reading-frame rule","volume":"34","author":"Fokkema","year":"2006","journal-title":"Muscle Nerve"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"White (2006). S.J.; den Dunnen, J.T. Copy number variation in the genome; the human DMD gene as an example. Cytogenet. Genome Res., 115, 240\u2013246.","DOI":"10.1159\/000095920"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tcb.2006.02.001","article-title":"Sparks, signals and shock absorbers: How dystrophin loss causes muscular dystrophy","volume":"16","author":"Batchelor","year":"2006","journal-title":"Trends Cell Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1007\/s12035-019-01845-w","article-title":"Dystrophin Dp71 and the Neuropathophysiology of Duchenne Muscular Dystrophy","volume":"57","author":"Naidoo","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.lfs.2017.11.035","article-title":"Altered membrane integrity in the progression of muscle diseases","volume":"192","author":"McElhanon","year":"2018","journal-title":"Life Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-981-13-1435-3_1","article-title":"An Overview of Muscle Atrophy","volume":"1088","author":"Ding","year":"2018","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.scr.2014.10.007","article-title":"Satellite cells from dystrophic muscle retain regenerative capacity","volume":"14","author":"Boldrin","year":"2015","journal-title":"Stem Cell Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/nm.3990","article-title":"Dystrophin expression in muscle stem cells regulates their polarity and asymmetric division","volume":"21","author":"Dumont","year":"2015","journal-title":"Nat. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1089\/scd.2014.0442","article-title":"Cancer Stem Cell Division: When the Rules of Asymmetry Are Broken","volume":"24","author":"Mukherjee","year":"2015","journal-title":"Stem Cells Dev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/ng.2974","article-title":"Dystrophin is a tumor suppressor in human cancers with myogenic programs","volume":"46","author":"Wang","year":"2014","journal-title":"Nat. Genet."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ruggieri, S., De Giorgis, M., Annese, T., Tamma, R., Notarangelo, A., Marzullo, A., Senetta, R., Cassoni, P., Notarangelo, M., and Ribatti, D. (2019). Dp71 Expression in Human Glioblastoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20215429"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/01.RES.0000237466.13252.5e","article-title":"Cardiac Sodium Channel Na v 1.5 Is Regulated by a Multiprotein Complex Composed of Syntrophins and Dystrophin","volume":"99","author":"Gavillet","year":"2006","journal-title":"Circ. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"C1502","DOI":"10.1152\/ajpcell.00435.2001","article-title":"Regulation of the cardiac L-type Ca2+ channel by the actin-binding proteins \u03b1-actinin and dystrophin","volume":"282","author":"Sadeghi","year":"2002","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Koenig, X., Dysek, S., Kimbacher, S., Mike, A.K., Cervenka, R., Lukacs, P., Nagl, K., Dang, X.B., Todt, H., and Bittner, R.E. (2011). Voltage-Gated Ion Channel Dysfunction Precedes Cardiomyopathy Development in the Dystrophic Heart. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020300"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"13663","DOI":"10.1073\/pnas.1512991112","article-title":"Dystrophin-glycoprotein complex regulates muscle nitric oxide production through mechanoregulation of AMPK signaling","volume":"112","author":"Garbincius","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1113\/jphysiol.2014.274878","article-title":"Nitric oxide synthase deficiency and the pathophysiology of muscular dystrophy","volume":"592","author":"Tidball","year":"2014","journal-title":"J. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/0883073818774439","article-title":"Descriptive Phenotype of Obsessive-Compulsive Symptoms in Males with Duchenne Muscular Dystrophy","volume":"33","author":"Lee","year":"2018","journal-title":"J. Child Neurol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/dmcn.12922","article-title":"Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations","volume":"58","author":"Ricotti","year":"2016","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_28","unstructured":"(2020, December 18). DMD\/BMD and the Brain. Available online: https:\/\/bindproject.eu\/."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"12575","DOI":"10.1038\/s41598-017-12981-5","article-title":"Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy","volume":"7","author":"Doorenweerd","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s00018-012-0926-4","article-title":"Molecular and functional heterogeneity of GABAergic synapses","volume":"69","author":"Fritschy","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Daoud, F., Candelario-Mart\u00ednez, A., Billard, J.-M., Avital, A., Khelfaoui, M., Rozenvald, Y., Guegan, M., Mornet, D., Jaillard, D., and Nudel, U. (2009). Role of Mental Retardation-Associated Dystrophin-Gene Product Dp71 in Excitatory Synapse Organization, Synaptic Plasticity and Behavioral Functions. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006574"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Taylor, P.J., Betts, G.A., Maroulis, S., Gilissen, C., Pedersen, R.L., Mowat, D.R., Johnston, H.M., and Buckley, M.F. (2010). Dystrophin Gene Mutation Location and the Risk of Cognitive Impairment in Duchenne Muscular Dystrophy. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0008803"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.pediatrneurol.2011.08.003","article-title":"Neurocognitive Profiles in Duchenne Muscular Dystrophy and Gene Mutation Site","volume":"45","author":"Lorusso","year":"2011","journal-title":"Pediatr. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s13311-018-00687-z","article-title":"Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy","volume":"15","author":"Shieh","year":"2018","journal-title":"Neurotherapeutics"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI117693","article-title":"Modulation of in vitro splicing of the upstream intron by modifying an intra-exon sequence which is deleted from the dystrophin gene in dystrophin Kobe","volume":"95","author":"Takeshima","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1006\/bbrc.1996.1375","article-title":"Induction of exon skipping of the dystrophin transcript in lymphoblastoid cells by transfecting an antisense oligodeoxynucleotide complementary to an exon recognition sequence","volume":"226","author":"Pramono","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1172\/JCI115244","article-title":"Exon skipping during splicing of dystrophin mRNA precursor due to an intraexon deletion in the dystrophin gene of Duchenne muscular dystrophy kobe","volume":"87","author":"Matsuo","year":"1991","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/0006-291X(90)92185-3","article-title":"A very small frame-shifting deletion within exon 19 of the Duchenne muscular dystrophy gene","volume":"170","author":"Matsuo","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0960-8966(93)90109-W","article-title":"The \u201crescue\u201d of dystrophin synthesis in boys with Duchenne muscular dystrophy","volume":"3","author":"Nicholson","year":"1993","journal-title":"Neuromuscul. Disord."},{"key":"ref_40","first-page":"1007","article-title":"Exon skipping and translation in patients with frameshift deletions in the dystrophin gene","volume":"53","author":"Sherratt","year":"1993","journal-title":"Am. J. Hum. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.nmd.2010.03.007","article-title":"Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: Implication for clinical trials","volume":"20","author":"Kinali","year":"2010","journal-title":"Neuromuscul. Disord."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ajpath.2011.03.050","article-title":"Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through","volume":"179","author":"Hoffman","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_43","first-page":"180","article-title":"Very mild muscular dystrophy associated with the deletion of 46% of dystrophin","volume":"343","author":"England","year":"1990","journal-title":"Nat. Cell Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/cphy.c140048","article-title":"The Dystrophin Complex: Structure, Function, and Implications for Therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr. Physiol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Fokkema","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Sun, C., Shen, L., Zhang, Z., and Xie, X. (2020). Therapeutic Strategies for Duchenne Muscular Dystrophy: An Update. Genes, 11.","DOI":"10.3390\/genes11080837"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.nmd.2020.08.285","article-title":"Casimersen treatment in eligible patients with Duchenne muscular dystrophy: Safety, tolerability, and pharmacokinetics over 144 weeks of treatment","volume":"30","author":"Kuntz","year":"2020","journal-title":"Neuromuscul. Disord."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e2270","DOI":"10.1212\/WNL.0000000000009233","article-title":"Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy","volume":"94","author":"Frank","year":"2020","journal-title":"Neurology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/acn3.51235","article-title":"Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1\/2 study","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.omtn.2018.02.004","article-title":"Saponins as Natural Adjuvant for Antisense Morpholino Oligonucleotides Delivery in vitro and in mdx Mice","volume":"11","author":"Wang","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1038\/s41467-018-03709-8","article-title":"Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle","volume":"9","author":"Novak","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","article-title":"Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases","volume":"45","author":"Tsoumpra","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_53","unstructured":"Sarepta Therapeutics (2020, December 17). Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51. Available online: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-positive-clinical-results."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Sardone, V., Zhou, H., Muntoni, F., Ferlini, A., and Falzarano, M.S. (2017). Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease. Molecules, 22.","DOI":"10.3390\/molecules22040563"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/nat.2018.0773","article-title":"Evaluating the Impact of Variable Phosphorothioate Content in Tricyclo-DNA Antisense Oligonucleotides in a Duchenne Muscular Dystrophy Mouse Model","volume":"29","author":"Aupy","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/acn3.579","article-title":"Placebo-controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy","volume":"5","author":"McDonald","year":"2018","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.nmd.2017.10.004","article-title":"A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy","volume":"28","author":"Goemans","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_58","first-page":"1","article-title":"Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy","volume":"19","author":"Schneider","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_59","unstructured":"Biomarin (2020, December 17). FDA Issues Complete Response Letter for KyndrisaTM for Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping. Available online: https:\/\/investors.biomarin.com\/2016-01-14-FDA-Issues-Complete-Response-Letter-for-KyndrisaTM-for-Duchenne-Muscular-Dystrophy-Amenable-to-Exon-51-Skipping."},{"key":"ref_60","unstructured":"European Medicines Agency (2020, December 17). Withdrawal of the Marketing Authorisation Application for Kyndrisa (Drisapersen). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/medicine-qa\/questions-answers-withdrawal-marketing-authorisation-application-kyndrisa-drisapersen_en.pdf."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"13456","DOI":"10.1093\/nar\/gku1115","article-title":"Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages","volume":"42","author":"Wan","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nbt.3948","article-title":"Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides","volume":"35","author":"Iwamoto","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_63","unstructured":"Wave Life Sciences (2020, December 17). Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy. Available online: https:\/\/ir.wavelifesciences.com\/news-releases\/news-release-details\/wave-life-sciences-announces-discontinuation-suvodirsen."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2217\/cer-2020-0095","article-title":"Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy","volume":"9","author":"Campbell","year":"2020","journal-title":"J. Comp. Eff. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1111\/jcmm.15319","article-title":"Effect of Ataluren on dystrophin mutations","volume":"24","author":"Berger","year":"2020","journal-title":"J. Cell. Mol. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.nmd.2018.06.009","article-title":"Personalized gene and cell therapy for Duchenne Muscular Dystrophy","volume":"28","author":"Wein","year":"2018","journal-title":"Neuromuscul. Disord."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.jip.2011.05.008","article-title":"Latest developments in the large-scale production of adeno-associated virus vectors in insect cells toward the treatment of neuromuscular diseases","volume":"107","author":"Galibert","year":"2011","journal-title":"J. Invertebr. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s43440-020-00134-x","article-title":"Muscle and cardiac therapeutic strategies for Duchenne muscular dystrophy: Past, present, and future","volume":"72","author":"Dulak","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"R102","DOI":"10.1093\/hmg\/ddz128","article-title":"AAV-based gene therapies for the muscular dystrophies","volume":"28","author":"Crudele","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Chiu, W., Hsun, Y.-H., Chang, K.-J., Yarmishyn, A.A., Hsiao, Y.-J., Chien, Y., Chien, C.S., Ma, C., Yang, Y.-P., and Tsai, P.-H. (2020). Current Genetic Survey and Potential Gene-Targeting Therapeutics for Neuromuscular Diseases. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21249589"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3892\/br.2020.1355","article-title":"Novel genetic therapeutic approaches for modulating the severity of \u03b2-thalassemia","volume":"13","author":"Amjad","year":"2020","journal-title":"Biomed. Rep."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ymthe.2019.01.002","article-title":"Development of Novel Mi-cro-dystrophins with Enhanced Functionality","volume":"27","author":"Ramos","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1089\/10430340260185085","article-title":"Adeno-associated virus vector-mediated mini-dystrophin gene therapy improves dystrophic muscle contractile function in mdx mice","volume":"13","author":"Watchko","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"16105","DOI":"10.1038\/ncomms16105","article-title":"Long-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy","volume":"8","author":"Servais","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/mt.2010.94","article-title":"Widespread Muscle Expression of an AAV9 Human Mini-dystrophin Vector After Intravenous Injection in Neonatal Dystrophin-deficient Dogs","volume":"18","author":"Kornegay","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9\u2013dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin immunity in Duchenne\u2019s muscular dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s41591-019-0594-0","article-title":"Non-immunogenic utrophin gene therapy for the treatment of muscular dystrophy animal models","volume":"25","author":"Song","year":"2019","journal-title":"Nat. Med."},{"key":"ref_79","unstructured":"Solid Biosciences (2020, December 19). Solid Biosciences Announces Clinical Hold On SGT-001 Phase I\/II Clinical Trial for Duchenne Muscular Dystrophy. Available online: https:\/\/investors.solidbio.com\/news-releases\/news-release-details\/solid-biosciences-announces-clinical-hold-sgt-001-phase-iii."},{"key":"ref_80","unstructured":"(2020, December 17). Sarepta Therapeutics Reports Sustained Functional Improvement Two Years After Treatment with SRP-9001, its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy. Available online: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-reports-sustained-functional-improvement."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/j.ajpath.2016.05.021","article-title":"B4GALNT2 (GALGT2) Gene Therapy Reduces Skeletal Muscle Pathology in the FKRP P448L Mouse Model of Limb Girdle Muscular Dystrophy 2I","volume":"186","author":"Thomas","year":"2016","journal-title":"Am. J. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"C476","DOI":"10.1152\/ajpcell.00456.2008","article-title":"Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice","volume":"296","author":"Martin","year":"2009","journal-title":"Am. J. Physiol. Physiol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/mt.2013.246","article-title":"Vascular delivery of rAAVrh74.MCK.GALGT2 to the gastrocnemius muscle of the rhesus macaque stimulates the expression of dystrophin and laminin \u03b12 surrogates","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.ymthe.2019.01.005","article-title":"rAAVrh74.MCK.GALGT2 Protects against Loss of Hemodynamic Function in the Aging mdx Mouse Heart","volume":"27","author":"Xu","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nm.3793","article-title":"Therapeutic genome editing: Prospects and challenges","volume":"21","author":"Cox","year":"2015","journal-title":"Nat. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1093\/nar\/gkg375","article-title":"A novel engineered meganuclease induces homologous recombination in yeast and mammalian cells","volume":"31","author":"Epinat","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1038\/nrg2842","article-title":"Genome editing with engineered zinc finger nucleases","volume":"11","author":"Urnov","year":"2010","journal-title":"Nat. Rev. Genet."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nbt.1755","article-title":"A TALE nuclease architecture for efficient genome editing","volume":"29","author":"Miller","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nbt.2842","article-title":"CRISPR-Cas systems for editing, regulating and targeting genomes","volume":"32","author":"Sander","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"9591","DOI":"10.1073\/pnas.1407473111","article-title":"Seamless modi-fication of wild-type induced pluripotent stem cells to the natural CCR5\u039432 mutation confers resistance to HIV infection","volume":"111","author":"Ye","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"eaan8081","DOI":"10.1126\/scitranslmed.aan8081","article-title":"Single-cut genome editing restores dystrophin expression in a new mouse model of muscular dystrophy","volume":"9","author":"Amoasii","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1126\/science.2662404","article-title":"The molecular basis of muscular dystrophy in the mdx mouse: A point mutation","volume":"244","author":"Sicinski","year":"1989","journal-title":"Science"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2015","journal-title":"Science"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2015","journal-title":"Science"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1161\/CIRCRESAHA.117.310996","article-title":"In Vivo Genome Editing Restores Dystrophin Expression and Cardiac Function in Dystrophic Mice","volume":"121","author":"Xu","year":"2017","journal-title":"Circ. Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"eaav4324","DOI":"10.1126\/sciadv.aav4324","article-title":"CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells","volume":"5","author":"Min","year":"2019","journal-title":"Sci. Adv."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1126\/science.aau1549","article-title":"Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy","volume":"362","author":"Amoasii","year":"2018","journal-title":"Science"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1172\/JCI136873","article-title":"Correction of muscular dystrophies by CRISPR gene editing","volume":"130","author":"Chemello","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Hakim, C.H., Wasala, N.B., Nelson, C.E., Wasala, L.P., Yue, Y., Louderman, J.A., Lessa, T.B., Dai, A., Zhang, K., and Jenkins, G.J. (2018). AAV CRISPR editing rescues cardiac and muscle function for 18 months in dystrophic mice. JCI Insight, 3.","DOI":"10.1172\/jci.insight.124297"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","article-title":"Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy","volume":"25","author":"Nelson","year":"2019","journal-title":"Nat. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nmeth.3993","article-title":"A multi-functional AAV-CRISPR-Cas9 and its host response","volume":"13","author":"Chew","year":"2016","journal-title":"Nat. Methods"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nbt.2808","article-title":"Improving CRISPR-Cas nuclease specificity using truncated guide RNAs","volume":"32","author":"Fu","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1101\/gr.162339.113","article-title":"Analysis of off-target effects of CRISPR\/Cas-derived RNA-guided endonucleases and nickases","volume":"24","author":"Cho","year":"2014","journal-title":"Genome Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/stem.3094","article-title":"CRISPR\/Cas9-Based Dystrophin Restoration Reveals a Novel Role for Dystrophin in Bioenergetics and Stress Resistance of Muscle Progenitors","volume":"37","author":"Matre","year":"2019","journal-title":"Stem Cells"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.stem.2018.03.022","article-title":"The Dystrophin Glycoprotein Complex Regulates the Epigenetic Activation of Muscle Stem Cell Commitment","volume":"22","author":"Chang","year":"2018","journal-title":"Cell Stem Cell"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"113086","DOI":"10.1016\/j.expneurol.2019.113086","article-title":"Stem cell-based therapies for Duchenne muscular dystrophy","volume":"323","author":"Sun","year":"2020","journal-title":"Exp. Neurol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jb\/mvy019","article-title":"The roles of muscle stem cells in muscle injury, atrophy and hypertrophy","volume":"163","author":"Fukada","year":"2018","journal-title":"J. Biochem."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/jor.24058","article-title":"Stem cells, blood vessels, and angiogenesis as major determinants for musculoskeletal tissue repair","volume":"37","author":"Huard","year":"2019","journal-title":"J. Orthop. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.15252\/emmm.201505636","article-title":"Intra-arterial transplantation of HLA-matched donor mesoangioblasts in Duchenne muscular dystrophy","volume":"7","author":"Cossu","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1083\/jcb.147.4.869","article-title":"Skeletal Myogenic Progenitors Originating from Embryonic Dorsal Aorta Coexpress Endothelial and Myogenic Markers and Contribute to Postnatal Muscle Growth and Regeneration","volume":"147","author":"Angelis","year":"1999","journal-title":"J. Cell Biol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1242\/dev.129.11.2773","article-title":"The meso-angioblast: A multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues","volume":"129","author":"Minasi","year":"2002","journal-title":"Development"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/ncomms1508","article-title":"Pericytes resident in postnatal skeletal muscle differentiate into muscle fibres and generate satellite cells","volume":"2","author":"Dellavalle","year":"2011","journal-title":"Nat. Commun."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/ncb1542","article-title":"Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells","volume":"9","author":"Dellavalle","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1126\/science.1082254","article-title":"Cell Therapy of -Sarcoglycan Null Dystrophic Mice Through Intra-Arterial Delivery of Mesoangioblasts","volume":"301","author":"Sampaolesi","year":"2003","journal-title":"Science"},{"key":"ref_118","first-page":"574","article-title":"Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs","volume":"444","author":"Sampaolesi","year":"2006","journal-title":"Nat. Cell Biol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e866","DOI":"10.1212\/WNL.0000000000006950","article-title":"Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial","volume":"92","author":"Taylor","year":"2019","journal-title":"Neurology"},{"key":"ref_120","first-page":"89","article-title":"Skeletal muscle generated from induced pluripotent stem cells\u2014Induction and application","volume":"9","author":"Takeda","year":"2017","journal-title":"World J. Stem Cells"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5966\/sctm.2013-0095","article-title":"Myogenic differentiation of muscular dystrophy-specific induced pluripotent stem cells for use in drug discovery","volume":"3","author":"Abujarour","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"12831","DOI":"10.1038\/srep12831","article-title":"Early pathogenesis of Duchenne muscular dystrophy modelled in patient-derived human induced pluripotent stem cells","volume":"5","author":"Shoji","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.celrep.2016.05.016","article-title":"Concordant but Varied Phenotypes among Duchenne Muscular Dystrophy Patient-Specific Myoblasts Derived using a Human iPSC-Based Model","volume":"15","author":"Choi","year":"2016","journal-title":"Cell Rep."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.stem.2016.01.021","article-title":"A Single CRISPR-Cas9 Deletion Strategy that Targets the Majority of DMD Patients Restores Dystrophin Function in hiPSC-Derived Muscle Cells","volume":"18","author":"Young","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.scr.2017.10.023","article-title":"A human iPS cell myogenic differentiation system permitting high-throughput drug screening","volume":"25","author":"Uchimura","year":"2017","journal-title":"Stem Cell Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.celrep.2018.03.091","article-title":"Three-Dimensional Human iPSC-Derived Artificial Skeletal Muscles Model Muscular Dystrophies and Enable Multilineage Tissue Engineering","volume":"23","author":"Maffioletti","year":"2018","journal-title":"Cell Rep."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"dmm034728","DOI":"10.1242\/dmm.034728","article-title":"Recapitulating muscle disease phenotypes with myotonic dystrophy 1 induced pluripotent stem cells: A tool for disease modeling and drug discovery","volume":"11","author":"Perlingeiro","year":"2018","journal-title":"Dis. Model. Mech."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fgene.2018.00114","article-title":"Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy","volume":"9","author":"Cordova","year":"2018","journal-title":"Front. Genet."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/4033","article-title":"Expression of full-length utrophin prevents muscular dystrophy in mdx mice","volume":"4","author":"Tinsley","year":"1998","journal-title":"Nat. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1093\/hmg\/ddv154","article-title":"Second-generation compound for the modulation of utrophin in the therapy of DMD","volume":"24","author":"Guiraud","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Moorwood, C., Lozynska, O., Suri, N., Napper, A.D., Diamond, S.L., and Khurana, T.S. (2011). Drug Discovery for Duchenne Muscular Dystrophy via Utrophin Promoter Activation Screening. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0026169"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1080\/21678707.2016.1240613","article-title":"Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy","volume":"4","author":"Spinazzola","year":"2016","journal-title":"Expert Opin. Orphan Drugs"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coph.2017.04.002","article-title":"Pharmacological advances for treatment in Duchenne muscular dystrophy","volume":"34","author":"Guiraud","year":"2017","journal-title":"Curr. Opin. Pharmacol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/4\/820\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:25:21Z","timestamp":1760160321000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/10\/4\/820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":133,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["jcm10040820"],"URL":"https:\/\/doi.org\/10.3390\/jcm10040820","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]}}}